RU99100578A - METHOD FOR TREATING EYE DISEASES - Google Patents

METHOD FOR TREATING EYE DISEASES

Info

Publication number
RU99100578A
RU99100578A RU99100578/14A RU99100578A RU99100578A RU 99100578 A RU99100578 A RU 99100578A RU 99100578/14 A RU99100578/14 A RU 99100578/14A RU 99100578 A RU99100578 A RU 99100578A RU 99100578 A RU99100578 A RU 99100578A
Authority
RU
Russia
Prior art keywords
eye diseases
treating eye
laser
days
diseases according
Prior art date
Application number
RU99100578/14A
Other languages
Russian (ru)
Other versions
RU2198641C2 (en
Inventor
Т.В. Шелковникова
В.В. Кашников
Original Assignee
Т.В. Шелковникова
Filing date
Publication date
Application filed by Т.В. Шелковникова filed Critical Т.В. Шелковникова
Priority to RU99100578A priority Critical patent/RU2198641C2/en
Priority claimed from RU99100578A external-priority patent/RU2198641C2/en
Publication of RU99100578A publication Critical patent/RU99100578A/en
Application granted granted Critical
Publication of RU2198641C2 publication Critical patent/RU2198641C2/en

Links

Claims (4)

1. Способ лечения глазных болезней, включающий воздействие лазерным лучом в режиме лазерстимуляции или лазеркоагуляции в сочетании с медикаментозной терапией, отличающийся тем, что медикаментозная терапия включает введение 0,1%-ного раствора даларгина в количестве по 0,3-0,7 мл в течение 10-15 сут.1. A method of treating eye diseases, including exposure to a laser beam in the mode of laser stimulation or laser coagulation in combination with drug therapy, characterized in that drug therapy includes the introduction of 0.1% dalargin solution in an amount of 0.3-0.7 ml per within 10-15 days. 2. Способ лечения глазных болезней по п.1, отличающийся тем, что лазерстимуляцию проводят на фоне подконъюнктивальных инъекций раствора даларгина. 2. A method of treating eye diseases according to claim 1, characterized in that the laser stimulation is carried out against the background of subconjunctival injection of dalargin solution. 3. Способ лечения глазных болезней по п.1, отличающийся тем, что раствор даларгина вводят под конъюнктиву через 1-3 сут после проведения лазеркоагуляции. 3. The method of treating eye diseases according to claim 1, characterized in that the dalargin solution is administered under the conjunctiva 1-3 days after laser coagulation. 4. Способ лечения глазных болезней по п. 1, отличающийся тем, что при поражении сетчатки или зрительного нерва раствор даларгина вводят парабульбарно через 1-3 сут после проведения лазеркоагуляции. 4. A method for the treatment of eye diseases according to claim 1, characterized in that in case of damage to the retina or optic nerve, the dalargin solution is administered parabulbarly 1-3 days after laser coagulation.
RU99100578A 1999-01-10 1999-01-10 Method for treating ophthalmic diseases RU2198641C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU99100578A RU2198641C2 (en) 1999-01-10 1999-01-10 Method for treating ophthalmic diseases

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU99100578A RU2198641C2 (en) 1999-01-10 1999-01-10 Method for treating ophthalmic diseases

Publications (2)

Publication Number Publication Date
RU99100578A true RU99100578A (en) 2000-11-27
RU2198641C2 RU2198641C2 (en) 2003-02-20

Family

ID=20214581

Family Applications (1)

Application Number Title Priority Date Filing Date
RU99100578A RU2198641C2 (en) 1999-01-10 1999-01-10 Method for treating ophthalmic diseases

Country Status (1)

Country Link
RU (1) RU2198641C2 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2413528C2 (en) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Exenatide and dalargin drug for treating diabetes, adminisration and therapy
EA038010B1 (en) * 2020-01-20 2021-06-22 Ооо "Промомед Рус" Stable succinic acid hexapeptide salts
WO2021211006A1 (en) 2020-04-13 2021-10-21 Federal State Budgetary Institution Center Of Biomedical Technologies Of Federal Medical And Biological Agency Inhaled hexapeptide for treating interleukin-6 related respiratory diseases

Similar Documents

Publication Publication Date Title
ES2204879T5 (en) NEUROPROTECTOR FOR THE EYE OF MAMMALS THROUGH ADMINISTRATION OF BLOCKERS OF THE POTASSIUM CHANNEL.
EP2663281B1 (en) Corneal delivery of cross-linking agents by iontophoresis for the treatment of keratoconus and related ophthalmic compositions
CA2427655A1 (en) Use of alpha adrenergic receptor agonist to reduce a decrease in neurosensory retinal function following laser therapy for choroidal neovascularization
JP2002534387A (en) Use of (2-imidazolin-2-ylamino) quinoxaline for the treatment of nerve damage
CA2584879A1 (en) Presbyopia treatment by lens alteration
WO2005030221A1 (en) Therapeutic agent for ageing macular degeneration
JP5913606B2 (en) Improved cross-linking composition effective for the treatment of keratoconus and introduced by iontophoresis
JPH0723325B2 (en) Ophthalmic formulation
JPH08511024A (en) Methods and compositions for reducing intraocular pressure
RU99100578A (en) METHOD FOR TREATING EYE DISEASES
ES2234428B1 (en) COMPOUNDS FOR THE TREATMENT OF THE DROUGHT OF THE OCULAR SURFACE CAUSED BY THE PHOTO-REFRECTIVE SURGERY.
RU2198641C2 (en) Method for treating ophthalmic diseases
Cangelosi et al. Cataract induction in rabbits with the Nd-YAG laser.
RU2120263C1 (en) Method for carrying out conservative treatment of burned eyes
RU2334496C1 (en) Method of prevention cicatrisation of outflow paths created during anti-glaucoma operation
JPH08325143A (en) Medicine for curing damage of corneal parenchyma
SU1474908A1 (en) Method of treating eye diseases
RU2199989C1 (en) Method for treating retina and optic nerve diseases of dystrophic genesis
RU98119433A (en) METHOD FOR TREATING CORNEAL DISEASES
RU2288677C2 (en) Method for photodynamic therapy of inflammatory diseases in anterior ocular segment
SU1602515A1 (en) Method of treating neovascularization of corneal shell
SU1357021A1 (en) Agent reducing the permeability of capillaries,dicreasing aggregation of thrombocytes and used for treatment of intraocular hemorrhages
SU1487902A1 (en) Method of treating lichorioidal detachments
SU1097321A1 (en) Method of treatment of eye diseases
Cassagne et al. Corneal Collagen Crosslinking Techniques: Updates